Developer docs
API playgroundTry for free, no card

Search company profiles

EPI Health

Full company profile

uuid000k6zh

Namestring
EPI Health
Websiteurl
epihealth.com
Company typeenum
Private
Founded yearint
2017
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCharleston, United States
HQ citystring
Charleston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
dermatology products, skin care treatments, prescription dermatology, therapeutic dermatology, dermatology pharmaceuticals
Product category
Dermatology Pharmaceuticals
No data
Cost components5 values
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EPI Health is a private dermatology-focused company operating in the skin health space. Per its firmographics description, the company is dedicated to the dermatology field, with operations based in Charleston, United States, and a workforce of 251–500 employees as of the available data.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
1Galderma
TypeBroad incumbent
Description

The world's largest independent dermatology company, offering a broad portfolio of dermatology products across therapeutic and aesthetic categories. Comparable as the dominant incumbent in the same dermatology market EPI Health serves.

2Sol-Gel Technologies
TypeDirect peer
Description

Specialty pharmaceutical company focused on dermatology with branded generic products. Comparable as a smaller dermatology-focused company with US commercial operations.

3Sebacia
TypeEmerging player
Description

Emerging dermatology company with a novel acne treatment using light-based technology. Comparable as a smaller commercial-stage dermatology company targeting a specific skin condition.

4Verrica Pharmaceuticals
TypeDirect peer
Description

Specialty pharmaceutical company developing and commercializing treatments for skin diseases. Comparable as a focused dermatology player with a commercial-stage product targeting a specific skin condition.

5Almirall
TypeBroad incumbent
Description

Global biopharmaceutical company focused on dermatology with a broad portfolio of medical dermatology products. Comparable as a dermatology-focused specialty pharma company with US commercial presence.

6Ortho Dermatologics (Bausch Health)
TypeBroad incumbent
Description

Division of Bausch Health focused on prescription dermatology products. Comparable as a major incumbent commercial-stage dermatology company competing for the same prescriber relationships.

7Aclaris Therapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on dermatology and immunology. Comparable as a smaller dermatology-focused company, though earlier in commercial maturity than EPI Health.

8Arcutis Biotherapeutics
TypeDirect peer
Description

Specialty dermatology biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin conditions. Directly comparable as a US-based commercial-stage dermatology company with a similar employee scale and product focus.

9Dermavant Sciences
TypeDirect peer
Description

Specialty pharmaceutical company dedicated to developing and commercializing innovative therapies in dermatology. Comparable as a focused dermatology commercial-stage company pursuing differentiated prescription products.

10Mayne Pharma
TypeBroad incumbent
Description

Specialty pharmaceutical company with a significant dermatology franchise focused on branded and generic topical products. Comparable as a broader dermatology player with overlapping product portfolio and US commercial operations.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EPI Health

Dermatology Pharmaceuticalsepihealth.com

EPI Health firmographics

Firmographics
Name
EPI Health
Website
https://epihealth.com
Company type
Private
Founded year
2017
Headcount range
251–500 employees
Ownership category
akta.pro rank

Where EPI Health is headquartered

Location

Headquarters

HQ city
Charleston
HQ country
United States
HQ region
North America

Markets served

EPI Health business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

EPI Health product offering

Product offering

Core offering

EPI Health is a private dermatology-focused company operating in the skin health space. Per its firmographics description, the company is dedicated to the dermatology field, with operations based in Charleston, United States, and a workforce of 251–500 employees as of the available data.

Differentiator

Problem solved

Functional benefit

Companies that use EPI Health

Customer profile

Ideal customer profiles1 record

EPI Health technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

EPI Health competitors and assessment

Company assessment

Broad incumbents

  • Galderma: The world's largest independent dermatology company, offering a broad portfolio of dermatology products across therapeutic and aesthetic categories. Comparable as the dominant incumbent in the same dermatology market EPI Health serves.
  • Almirall: Global biopharmaceutical company focused on dermatology with a broad portfolio of medical dermatology products. Comparable as a dermatology-focused specialty pharma company with US commercial presence.
  • Ortho Dermatologics (Bausch Health): Division of Bausch Health focused on prescription dermatology products. Comparable as a major incumbent commercial-stage dermatology company competing for the same prescriber relationships.
  • Mayne Pharma: Specialty pharmaceutical company with a significant dermatology franchise focused on branded and generic topical products. Comparable as a broader dermatology player with overlapping product portfolio and US commercial operations.

Direct peers

  • Sol-Gel Technologies: Specialty pharmaceutical company focused on dermatology with branded generic products. Comparable as a smaller dermatology-focused company with US commercial operations.
  • Verrica Pharmaceuticals: Specialty pharmaceutical company developing and commercializing treatments for skin diseases. Comparable as a focused dermatology player with a commercial-stage product targeting a specific skin condition.
  • Aclaris Therapeutics: Clinical-stage biopharmaceutical company focused on dermatology and immunology. Comparable as a smaller dermatology-focused company, though earlier in commercial maturity than EPI Health.
  • Arcutis Biotherapeutics: Specialty dermatology biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin conditions. Directly comparable as a US-based commercial-stage dermatology company with a similar employee scale and product focus.
  • Dermavant Sciences: Specialty pharmaceutical company dedicated to developing and commercializing innovative therapies in dermatology. Comparable as a focused dermatology commercial-stage company pursuing differentiated prescription products.

Emerging players

  • Sebacia: Emerging dermatology company with a novel acne treatment using light-based technology. Comparable as a smaller commercial-stage dermatology company targeting a specific skin condition.

Market position

Strengths3 records

Weaknesses4 records

Key risks4 records

Key highlights4 records

Customer concentration

EPI Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EPI Health leadership team

Management profile

Number of profiles

EPI Health funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EPI Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EPI Health

What does EPI Health do?

EPI Health is a private dermatology-focused company operating in the skin health space. Per its firmographics description, the company is dedicated to the dermatology field, with operations based in Charleston, United States, and a workforce of 251–500 employees as of the available data.

When was EPI Health founded?

EPI Health was founded in 2017. It employs 251 to 500 people.

Where is EPI Health based?

EPI Health is headquartered in Charleston, United States, in the North America region.

Who are EPI Health's main competitors?

Broad incumbents on record are Galderma, Almirall, Ortho Dermatologics (Bausch Health) and Mayne Pharma. Direct peers are Sol-Gel Technologies, Verrica Pharmaceuticals, Aclaris Therapeutics, Arcutis Biotherapeutics and Dermavant Sciences. Sebacia is listed as an emerging player.

Does EPI Health have an API?

No public API is recorded for EPI Health.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNovan Moves Forward with Unified Corporate BrandingNovan announced its commercial subsidiary EPI Health will adopt the Novan brand, unifying the company ahead of the commercial launch of berdazimer gel 10.3% (SB206). The FDA has accepted Novan's NDA submission for the gel to treat molluscum contagiosum. The company also has a pipeline of product candidates using its NITRICIL technology platform.GlobeNewswireEPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®Novan, EPI Health, and MC2 Therapeutics presented survey data on psoriasis patients' topical treatment preferences at the 42nd Annual Fall Clinical Dermatology Conference. Most patients (83.9%) had moderate psoriasis, and nearly 80% would discontinue treatment without improvement in two weeks. Formulation attributes like application feel and non-staining were rated most important.GlobeNewswireEPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 ConferenceNovan, EPI Health, and MC2 Therapeutics presented subgroup analysis data from a Phase 3 trial of WYNZORA cream at the Skin of Color Update 2022 conference. The analysis showed skin of color patients (36% of subjects) achieved similar efficacy to the total population, with 37.4% achieving PGA success versus 38.7% overall, and no hypopigmentation cases were reported.GlobeNewswireNovan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-MarketNovan, Inc. announced a registered direct offering to sell approximately 2,080,696 shares of its common stock and accompanying warrants for gross proceeds of about $15.0 million. The offering is expected to close on or about June 13, 2022, and the proceeds will fund research and development activities, including regulatory preparations for its product candidate, SB206. Novan is primarily focused on developing therapies for skin diseases and recently acquired EPI Health to enhance its commercial capabilities.PR NewswireEVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INCEvening Post Group has sold its specialty pharmaceutical subsidiary, EPI Health, to Novan, Inc for a base purchase price of $27.5 million with potential earnouts reaching approximately $50 million. This acquisition allows Novan to integrate EPI Health's FDA-approved dermatology product portfolio and sales force into its existing operations. The transaction was announced on March 11, 2022, marking a strategic expansion for the public dermatology company.BenzingaNovan Acquires EPI Health To Bolster Commercial Force For Potential Marketing Of Its lead ProductsNovan Inc (NASDAQ:NOVN) has acquired EPI Health LLC, a specialty pharmaceutical company focused on the U.S. dermatology market, for $27.5 million in deal consideration consisting of $11 million in cash and $16.5 million in a seller's note, with up to an additional $23.5 million in potential future milestone payments. EPI Health brings a product portfolio of four prescription products across psoriasis, rosacea, dermatosis, and acne, along with approximately 100 staff covering 42 sales territories in the U.S. The acquisition is designed to build commercial infrastructure for Novan as it prepares for the planned NDA submission of its lead product candidate SB206 (berdazimer gel 10.3%).PR NewswireEPI Health und MC2 Therapeutics geben die US-Einführung der Wynzora®-Creme gegen Plaque-Psoriasis (Calcipotrien und Betamethasondipropionat w/w 0,005 %/0,064 %) bekanntEPI Health and MC2 Therapeutics announced on July 19, 2021, the commercial availability of Wynzora® Cream in the United States for the topical treatment of plaque psoriasis in adults. Wynzora is the first and only water-based cream utilizing the proprietary PAD™ technology to combine calcipotriol and betamethasone dipropionate, addressing nearly 8 million psoriasis patients in the US. The launch expands EPI Health's dermatology portfolio and represents a new treatment option combining efficacy, safety, and user comfort in a single topical product.PR NewswireEPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)EPI Health and MC2 Therapeutics announced the commercial launch of Wynzora® Cream in the United States on July 19, 2021, a topical treatment for plaque psoriasis in adults using the companies' proprietary PAD™ technology. Wynzora is the first and only water-based cream combining calcipotriene and betamethasone dipropionate, addressing a market where topical therapy is the first-line treatment for 95% of the nearly 8 million psoriasis patients in the US. The product is now available for commercial supply through EPI Health's distribution network, with MC2 Therapeutics having developed the formulation.PR NewswireEPI Health y MC2 Therapeutics lanzan la crema Wynzora® para la psoriasis en placa en EE.UU.EPI Health and MC2 Therapeutics announced the commercial launch in the United States of Wynzora® cream, a topical treatment for plaque psoriasis in adults, available from July 19, 2021. Wynzora is the first and only water-based cream using the proprietary PAD™ technology that combines calcipotriene and betamethasone dipropionate, offering efficacy, safety, and convenience in a single once-daily product. Phase 3 trials conducted at multiple sites in the US and EU demonstrated compelling clinical efficacy and a favorable safety profile, with patients rating the product at 84% on ease of application, non-greasy feel, and minimal disruption to daily routine.PR NewswireEPI Health et MC2 Therapeutics annoncent le lancement aux États-Unis de Wynzora® Cream pour le psoriasis en plaques (calcipotriène et dipropionate de bétaméthasone, m/m 0,005 %/0,064 %)EPI Health and MC2 Therapeutics announced the commercial availability of Wynzora® Cream in the United States on July 19, 2021, for the topical treatment of plaque psoriasis in adults aged 18 and older. The product combines calcipotriene and betamethasone dipropionate in an aqueous cream base using MC2 Therapeutics' proprietary PAD™ technology, which the companies describe as the first and only water-based cream to deliver this drug combination with improved usability. The launch targets the approximately 8 million psoriasis patients in the United States, with topical therapies serving as first-line treatment for 95% of adult patients.